Nematocidal activity of MK-801 analogs and related drugs. Structure-activity relationships.

A series of dibenzo[a,d]cycloalkenimines were evaluated for their affinity to the (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801) binding site in Caenorhabditis elegans membranes and their nematocidal activity. The (+)-MK-801 enantiomer (1) had a higher affinity (Kd = 240 nM) for its specific binding site and was a more potent nematocidal agent than the (-)-MK-801 enantiomer (-1). Ring expansion to form the dibenzo[a,d]cyclooctenimine analogs generally resulted in more potent compounds. The most potent of this series (23) was approximately 7-fold more potent than (+)-MK-801. A good correlation was established between binding affinities and nematocidal activity for all of the analogs that were tested. However, there was no correlation between binding to C. elegans membranes and affinity for mammalian MK-801 binding sites. Other noncompetitive inhibitors of the mammalian N-methyl-D-aspartate site were examined, and a series of diphenylguanidines were identified as potent competitive inhibitors of MK-801 binding to C. elegans membranes, in addition to displaying potent nematocidal activity. The most potent diphenylguanidine analog (24) was approximately 80-fold more potent than (+)-MK-801 in both its affinity for the MK-801 binding site and as a nematocidal agent. Molecular modeling studies support the hypothesis that the diphenylguanidines and MK-801 are binding to the same site and suggest that more potent compounds may be developed by effective modeling of the existing compounds.

Cochlioquinone A, a nematocidal agent which competes for specific [3H]ivermectin binding sites.

Cochlioquinone A, isolated from the fungus Helminthosporium sativum, was found to have nematocidal activity. Cochlioquinone A is a competitive inhibitor of specific [3H]ivermectin binding suggesting that cochlioquinone A and ivermectin interact with the same membrane receptor.

MK-801 is a potent nematocidal agent. Characterization of MK-801 binding sites in Caenorhabditis elegans.

MK-801, an N-methyl-D-aspartate antagonist in mammalian brain tissue, is a potent nematocidal agent. Specific MK-801 binding sites have been identified and characterized in a membrane fraction prepared from the free-living nematode Caenorhabditis elegans. The high-affinity MK-801 binding site has an apparent dissociation constant, Kd, of 225 nM. Unlike the MK-801 binding site in mammalian tissues, the C. elegans binding site is not effected by glutamate or glycine, and polyamines are potent inhibitors of specific MK-801 binding.

Identification of gamma-aminobutyric acid and its binding sites in Caenorhabditis elegans.

Gamma-aminobutyric acid (GABA), glutamate decarboxylase and GABA-transaminase were identified in the nematode Caenorhabditis elegans. The concentration of GABA in C. elegans (0.14 micrograms/mg protein) is approximately 10-fold lower than the concentration of GABA in rat brain. Glutamate decarboxylase and GABA-transaminase, the GABA anabolic and catabolic enzymes, are also present in C. elegans. Crude membrane fractions were prepared from C. elegans and used to study specific [3H] GABA binding sites. GABA binds to C. elegans membranes with high affinity (37 nM) and low capacity (Bmax = 2.25 pmol/mg protein). Muscimol is a competitive inhibitor of specific GABA binding with a KI value of 120 nM. None of the other GABA agonists or antagonists inhibited greater than 40% of the specific GABA binding at concentrations up to 10(-4)M. Thirteen spider venoms were examined as possible GABA agonists or antagonists, the venom from Calilena agelenidae inhibits specific GABA binding with a KI value of 6 nl/ml. These results suggest that GABA has a physiological role as a neurotransmitter in C. elegans.

Mouse submaxillary gland renin. Purification and properties of minor forms, which include several differently processed forms of the major gene product and a second gene product.

Three minor forms of renin from the submaxillary glands of male mice called D1, D2, and E have been purified to homogeneity. Their amino acid compositions are identical to the principal form of mouse submaxillary gland renin (renin A), except for 1, 1, and 2 extra arginine residues, respectively. The electrophoretic mobility of renin D2 does not change upon reduction, indicating that its heavy and light chains are linked by more than a disulfide bond. The light chain of renin D1 has an electrophoretic mobility different from the light chain of renin A. Renin D2 is proposed to be renin A with an arginine-arginine dipeptide connecting the carboxyl terminus of the heavy chain to the NH2 terminus of the light chain, with the light chain missing the carboxyl-terminal arginine of renin A. Renin D1 is suggested to be renin D2 with the peptide bond between an arginine and the NH2 terminus of the light chain cleaved. Renin E is proposed to be renin D1 plus the carboxyl-terminal arginine of the light chain. A fourth minor form of male mouse submaxillary renin, called renin B/A, has been purified to homogeneity in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and in isoelectric focusing. Renin B/A seems to be a second renin gene product which is difficult to separate from renin A. Renin B/A has an amino acid composition significantly different from renin A, and all three preparations of B/A had compositions significantly different from one another. For renin B/A, the light chain sequence and the first 53 NH2-terminal residues of its heavy chain sequence were identical to renin A.